{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 266,
  "pageCount": 415,
  "prevPage": 265,
  "nextPage": 267,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses press release excerpts to establish a pattern of behavior or conflict of interest.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/266",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-266",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Miller was involved with beloranib as the “principal investigator,” a drug developed by Zafgen which was the last high-flier PWS stock, which imploded after development was terminated due to fatalities from pulmonary embolism and thrombotic events.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2ac-d77242193b44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.49,
        "y": 0.41
      },
      "kind": "paragraph",
      "text": "“PWS is a devastating condition that leads to life-threatening obesity and affects patients and caretakers alike,” said Dr. Jennifer Miller, Pediatric Endocrinologist and Associate Professor of Medicine at University of Florida Health. “This Phase 3 trial is a significant step in meeting the urgent need for novel and effective treatment options that have the potential to positively impact the lives of patients and families living with this disease.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "545872e0-75d1-4bf4-a491-10e97b6804ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.4,
        "x": 0.49,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b587106-affe-4d80-a6db-7091bea4980f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.4,
        "x": 0.07,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0529c4f-e308-4fb4-9b50-9a785fd0e4c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.07,
        "y": 0.43
      },
      "kind": "paragraph",
      "text": "“These results are very exciting for the treatment of PWS, as most patients showed improvements in body weight, hunger-related behaviors, and body fat content, despite the increased food intake included in the trial design,” explained Dr. Jennifer Miller, Associate Professor of Pediatric Endocrinology, University of Florida, and Principal Investigator for the study. “PWS is a complex genetic disease that is difficult to treat and the results of this trial demonstrate that beloranib has a beneficial impact on this underserved patient population. Notably, we were encouraged by reports of fullness, a first-time occurrence for PWS patients who otherwise lack the capacity to feel sated after meals.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfb02937-ca2e-4901-a895-31c785c703f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Zafgen press releases, 2014",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaa43b59-295a-44e3-9f7d-136000797b6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“These results are very exciting for the treatment of PWS, as most patients showed improvements in body weight, hunger-related behaviors, and body fat content, despite the increased food intake included in the trial design,” explained Dr. Jennifer Miller — Zafgen Press Release, 2014.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2ac-db857b24a5d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.07,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: https://zafgen.gcs-web.com/news-releases/news-release-details/zafgen-announces-initial-results-phase-2a-study-beloranib; https://zafgen.gcs-web.com/news-releases/news-release-details/zafgen-announces-initiation-phase-3-trial-beloranib-prader-willi;",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f2b58c6-74cf-48cb-8cd3-f452ab6a39db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Miller was involved with beloranib as the “principal investigator,” a drug developed by Zafgen which was the last high-flier PWS stock, which imploded after development was terminated due to fatalities from pulmonary embolism and thrombotic events. Zafgen’s press releases feature Miller talking up the drug as “very exciting.”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a0b40ac-3b6c-4913-9372-05643017e18f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "4e813c58-e83d-458f-888c-259372ee4b22",
      "evidence": "Uses public statements to expose potential conflicts or contradictions in professional conduct.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}